These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23564182)

  • 1. Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells.
    Voswinkel J; Francois S; Gorin NC; Chapel A
    Immunol Res; 2013 Jul; 56(2-3):241-8. PubMed ID: 23564182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review.
    Voswinkel J; Francois S; Simon JM; Benderitter M; Gorin NC; Mohty M; Fouillard L; Chapel A
    Clin Rev Allergy Immunol; 2013 Oct; 45(2):180-92. PubMed ID: 23296948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.
    Grégoire C; Ritacco C; Hannon M; Seidel L; Delens L; Belle L; Dubois S; Vériter S; Lechanteur C; Briquet A; Servais S; Ehx G; Beguin Y; Baron F
    Front Immunol; 2019; 10():619. PubMed ID: 31001253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single administration of human adipose tissue-derived mesenchymal stromal cells (MSC) induces durable and sustained long-term regulation of inflammatory response in experimental colitis.
    Alves VBF; de Sousa BC; Fonseca MTC; Ogata H; Caliári-Oliveira C; Yaochite JNU; Rodrigues Júnior V; Chica JEL; da Silva JS; Malmegrim KCR; Pernomian L; Cardoso CR
    Clin Exp Immunol; 2019 May; 196(2):139-154. PubMed ID: 30663040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases.
    Grégoire C; Lechanteur C; Briquet A; Baudoux É; Baron F; Louis E; Beguin Y
    Aliment Pharmacol Ther; 2017 Jan; 45(2):205-221. PubMed ID: 27878827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review.
    Ko JZ; Johnson S; Dave M
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33440772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human mesenchymal stem cell therapy in the management of luminal and perianal fistulizing Crohn's disease - review of pathomechanism and existing clinical data.
    Bor R; Fábián A; Farkas K; Molnár T; Szepes Z
    Expert Opin Biol Ther; 2018 Jul; 18(7):737-745. PubMed ID: 29939815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots?
    Griffin MD; Elliman SJ; Cahill E; English K; Ceredig R; Ritter T
    Stem Cells; 2013 Oct; 31(10):2033-41. PubMed ID: 23766124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease.
    Tobin LM; Healy ME; English K; Mahon BP
    Clin Exp Immunol; 2013 May; 172(2):333-48. PubMed ID: 23574329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease Model.
    Soontararak S; Chow L; Johnson V; Coy J; Wheat W; Regan D; Dow S
    Stem Cells Transl Med; 2018 Jun; 7(6):456-467. PubMed ID: 29635868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cell effects on T-cell effector pathways.
    Duffy MM; Ritter T; Ceredig R; Griffin MD
    Stem Cell Res Ther; 2011 Aug; 2(4):34. PubMed ID: 21861858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease.
    Fan X; Guo D; Cheung AMS; Poon ZY; Yap CS; Goh SE; Guo D; Li H; Bari S; Li S; Lim KH; Hwang WYK
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):1971-1980. PubMed ID: 29883796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease.
    Ciccocioppo R; Bernardo ME; Sgarella A; Maccario R; Avanzini MA; Ubezio C; Minelli A; Alvisi C; Vanoli A; Calliada F; Dionigi P; Perotti C; Locatelli F; Corazza GR
    Gut; 2011 Jun; 60(6):788-98. PubMed ID: 21257987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats.
    Aksu AE; Horibe E; Sacks J; Ikeguchi R; Breitinger J; Scozio M; Unadkat J; Feili-Hariri M
    Clin Immunol; 2008 Jun; 127(3):348-58. PubMed ID: 18387852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Th17 Pathway As a Target for Multipotent Stromal Cell Therapy in Dogs: Implications for Translational Research.
    Kol A; Walker NJ; Nordstrom M; Borjesson DL
    PLoS One; 2016; 11(2):e0148568. PubMed ID: 26872054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.
    Duijvestein M; Vos AC; Roelofs H; Wildenberg ME; Wendrich BB; Verspaget HW; Kooy-Winkelaar EM; Koning F; Zwaginga JJ; Fidder HH; Verhaar AP; Fibbe WE; van den Brink GR; Hommes DW
    Gut; 2010 Dec; 59(12):1662-9. PubMed ID: 20921206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSCT recipients have specific tolerance to MSC but not to the MSC donor.
    Sundin M; Barrett AJ; Ringdén O; Uzunel M; Lönnies H; Dackland AL; Christensson B; Blanc KL
    J Immunother; 2009 Sep; 32(7):755-64. PubMed ID: 19561533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.
    Bonig H; Kuçi Z; Kuçi S; Bakhtiar S; Basu O; Bug G; Dennis M; Greil J; Barta A; Kállay KM; Lang P; Lucchini G; Pol R; Schulz A; Sykora KW; Teichert von Luettichau I; Herter-Sprie G; Ashab Uddin M; Jenkin P; Alsultan A; Buechner J; Stein J; Kelemen A; Jarisch A; Soerensen J; Salzmann-Manrique E; Hutter M; Schäfer R; Seifried E; Paneesha S; Novitzky-Basso I; Gefen A; Nevo N; Beutel G; Schlegel PG; Klingebiel T; Bader P
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mesenchymal stem cells and immunomodulation: toward new immunosuppressive strategies for the treatment of autoimmune diseases?].
    Larghero J; Vija L; Lecourt S; Michel L; Verrecchia F; Farge D
    Rev Med Interne; 2009 Mar; 30(3):287-99. PubMed ID: 18930338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.